Looking forward to the future, with the continuous deepening of scientific research and the rapid development of technology, multi-tumor cooperation will be the direction of our joint exploration.
As a major public health problem that threatens human health, the prevention and treatment of cancer has always been the top priority in the field of medical research. With the rapid development of science and technology, the R&D and clinical application of oncology drugs are in an unprecedented active period, with new drugs emerging in an endless stream and treatment methods changing with each passing day. However, how to efficiently and safely translate these innovations into clinical practice, improve the treatment effect of cancer, and reduce the burden on patients is a major challenge we face.
In this context, on the morning of June 23, 2024, the inaugural meeting of the Oncology Drug Clinical Research Professional Committee of the China Medical Education Association and the first Pujiang Oncology Drug Clinical Research Academic Annual Conference were successfully held in Shanghai. Academician Huang Zhengming, Life Honorary President of China Medical Education Association/President of the Chinese Academy of United Nations-International Academy of Ecological Life and Life Safety, Mr. Yang Xinbo, Executive Deputy Secretary-General of China Medical Education Association, Mr. Jia Wannian, former Vice President, Professor Yu Xiaoli, Assistant President of Fudan University Cancer Hospital, Professor Zhang Jian, Medical Director of the Ward of Medical Oncology/Phase I Clinical Research Center, Fudan University Cancer Hospital, Professor Li Hengyu, Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital), Members of the preparatory group of the Oncology Drug Clinical Research Committee and more than 100 representatives from online and offline attended the meeting.
Professor Yu Xiaoli from Fudan University Cancer Hospital made an opening speech for the inaugural meeting, pointing out that in today's era, the research and development of anti-tumor drugs is breaking through the traditional boundaries at an unprecedented speed, and the field of clinical research of oncology drugs is experiencing unprecedented vigorous development. As a leader in the field of cancer treatment in China, Fudan University Cancer Hospital has always attached great importance to and actively promoted the in-depth development of clinical trials of cancer drugs, and has achieved fruitful results. The establishment of the Oncology Drug Clinical Research Committee of the China Medical Education Association is undoubtedly a milestone in the journey of cancer treatment for Fudan Oncology and its colleagues in the industry, marking a solid step forward in exploration, innovation and deepening research.
Jia Wannian, vice president of the China Medical Education Association, read out the approval letter on the application for the establishment of the Tumor Drug Clinical Research Professional Committee of the China Medical Education Association. Mr. Yang Xinbo, Executive Deputy Secretary-General, read out the list of proposed chairmen, vice chairmen, secretary-generals, deputy secretary-generals and standing committee members of the special committee, and organized elections (online and offline voting) to elect the first members of the Oncology Drug Clinical Research Professional Committee of the China Medical Education Association. Deputy Secretary-General Yang Xinbo announced the election results: Professor Zhang Jian was elected as the chairman; Professor Li Hengyu was elected vice chairman and secretary general; Professor Wang Shulian, Professor Shi Yehui, Professor Li Yongsheng, Professor Yang Jin, Professor Hu Jiong, Professor Yao Herui, Professor Cui Jiuwei, Professor Si Lu and Professor Guan Xiaoxiang served as the vice chairmen and 24 standing committee members.
Academician Huang Zhengming, lifelong honorary president of China Medical Education Association, presented the chairmanship certificate and plaque to Professor Zhang Jian. Subsequently, Vice President Jia Wannian issued a certificate to the vice chairman, Deputy Secretary-General Yang Xinbo issued a letter of appointment to the chairman and deputy secretary-general, and Professor Zhang Jian issued a certificate to the Standing Committee members present.
Academician Huang Zhengming, Honorary Life President of China Medical Education Association, expressed warm congratulations on the establishment of the Oncology Drug Clinical Research Professional Committee of China Medical Education Association, and expressed sincere greetings and heartfelt wishes to the newly elected leading members and all members of the special committee.
He pointed out that as the vanguard of national medical education, the China Medical Education Association, a national advanced social organization and a 4A-level association, has always taken responsibility, responsibility and dedication as the goals and tasks of struggle, adhered to the purpose of "education-oriented, talent training", adhered to the idea of "academic legislature, science and technology strength, service and prosperity", established the development concept of "academic-rooted, science and technology-based, service-oriented", and took politics, organization and discipline as the basic criteria for the development of the association, and closely focused on the country's strategy. Actively undertake the tasks of national ministries and commissions, strengthen the association's own construction, resolutely take the road of innovation and development, run characteristics, brands, and fame, and strive to realize the dream of a first-class social organization in the country. At the same time, he also put forward valuable opinions and suggestions for the future work of the special committee.
Professor Zhang Jian, chairman of the committee, gave a detailed introduction to the background of the establishment of the special committee and the future work plan. He also pointed out that in the future, the work of the special committee will focus on the following six aspects: 1) evaluate and review the R&D and clinical trials of tumor drugs to ensure their scientific and compliance; 2) Analyze and evaluate the clinical trial data of oncology drugs to determine the safety and efficacy of the drugs, and provide a scientific basis for the approval and marketing of drugs; 3) Monitor and evaluate the adverse reactions and safety of drugs, and detect and report adverse reactions in a timely manner; 4) Supervise and guide the clinical research of drugs to improve the quality and efficiency of clinical research; 5) monitor the performance of oncology drugs after marketing, and identify and resolve potential safety issues or adverse events in a timely manner; 6) Provide professional advice and guidance for the approval, supervision and use of oncology drugs; It also shows that the establishment of this committee aims to build a high-end platform integrating academic exchanges, talent training and scientific research cooperation, focusing on key links such as cutting-edge research, clinical trial design, ethical review, data management and analysis of tumor drugs, and promoting the overall improvement of the clinical research level of cancer drugs in mainland China through the integration of resources and gathering wisdom, accelerating the pace of clinical application of innovative drugs, and bringing more treatment options and hope to cancer patients.
Subsequently, the first "Pujiang Oncology Drug Clinical Research Academic Annual Conference" was successfully held.
In the warm glow of the summer solstice, everyone witnessed the birth of the special committee, which is not only an important milestone in the field of clinical research of oncology drugs in mainland China, but also an expectation for future cooperation and progress. Looking forward to the future, with the continuous deepening of scientific research and the rapid development of technology, multi-tumor cooperation will be the direction of our joint exploration. This means that we need to cross the boundaries of traditional research, break down information silos, and build a more open and inclusive platform for cooperation.
By integrating multidisciplinary resources and sharing research results, we can more effectively address the complexity and diversity of cancer treatment, promote the progress of precision medicine, and provide patients with more personalized and efficient treatment options. We believe that through joint efforts, more breakthroughs will be made in the clinical research of cancer drugs in the future, bringing the spring of life to cancer patients around the world, defying challenges, being brave in innovation, and jointly writing a new chapter in the fight against cancer.